Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Eloxx Pharmaceuticals, Inc. ELOX
$3.71
-$0.34 (-9.07%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
8860412.00000000
-
week52high
19.20
-
week52low
1.70
-
Revenue
0
-
P/E TTM
0
-
Beta
2.70311400
-
EPS
-14.88000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 23 мая 2022 г. |
| HC Wainwright & Co. | Neutral | Neutral | 09 мая 2022 г. |
| Oppenheimer | Outperform | 17 дек 2021 г. | |
| HC Wainwright & Co. | Neutral | Neutral | 18 ноя 2021 г. |
| HC Wainwright & Co. | Neutral | Neutral | 11 ноя 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Walts Alan Edmund | A | 2859 | 2859 | 30 янв 2023 г. |
| Androski Lindsay | A | 2859 | 2859 | 30 янв 2023 г. |
| Kariv Tomer | A | 2859 | 2859 | 30 янв 2023 г. |
| Rubin Steven D | A | 2859 | 2859 | 30 янв 2023 г. |
| MODUR VIJAY | A | 30000 | 30000 | 25 янв 2023 г. |
| Aggarwal Sumit | A | 68700 | 68700 | 25 янв 2023 г. |
| Androski Lindsay | A | 40000 | 40000 | 01 июл 2022 г. |
| Walts Alan Edmund | A | 20000 | 20000 | 15 июн 2022 г. |
| Nussbaum Ran | A | 20000 | 20000 | 15 июн 2022 г. |
| PAREKH RAJESH B | A | 20000 | 20000 | 15 июн 2022 г. |
Новостная лента
Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
GlobeNewsWire
06 мар 2023 г. в 16:10
WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it will present at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13th at 12:00 PM ET.
5 Hot Penny Stocks Exploding After News This Week
PennyStocks
05 янв 2023 г. в 09:39
Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal
Zacks Investment Research
16 сент 2022 г. в 12:48
Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.